Current key issues in transcatheter aortic valve replacement undergoing a paradigm shift

In Chang Hwang, Kentaro Hayashida, Hyo Soo Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

As a new technology in the management of valvular heart disease, transcatheter aortic valve replacement (TAVR) has drawn much attention since its emergence. To date, numerous studies have investigated the safety and efficacy of TAVR in patients of various risk profiles with severe aortic stenosis (AS) and demonstrated comparable or superior outcomes of TAVR when compared with surgical aortic valve replacement (SAVR). The favorable outcomes of TAVR in inoperable patients, as well as in high- and intermediaterisk patients, are endorsed in current guidelines, and trials of low-risk patients have shown non-inferior or even superior results of TAVR than for SAVR, suggesting that the clinical indications of TAVR can be expanded to low-risk patients. Moreover, a therapeutic role of TAVR has been suggested in various aortic valve (AV) diseases, such as bicuspid AV, moderate AS with heart failure, aortic regurgitation, and bioprosthetic valve failure. In this review, we summarize the current issues of TAVR in various patient populations and discuss the expanding clinical indications of TAVR, which are driving a major paradigm shift in the management of AV disease.

Original languageEnglish
Pages (from-to)952-962
Number of pages11
JournalCirculation Journal
Volume83
Issue number5
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Aortic Valve
Aortic Diseases
Aortic Valve Stenosis
Surgical Instruments
Transcatheter Aortic Valve Replacement
Heart Valve Diseases
Aortic Valve Insufficiency
Heart Failure
Guidelines
Technology
Safety
Population
Therapeutics

Keywords

  • Aortic stenosis
  • Surgical aortic valve replacement
  • Transcatheter aortic valve implantation
  • Transcatheter aortic valve replacement
  • Valve-in-valve

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Current key issues in transcatheter aortic valve replacement undergoing a paradigm shift. / Hwang, In Chang; Hayashida, Kentaro; Kim, Hyo Soo.

In: Circulation Journal, Vol. 83, No. 5, 01.01.2019, p. 952-962.

Research output: Contribution to journalArticle

Hwang, In Chang ; Hayashida, Kentaro ; Kim, Hyo Soo. / Current key issues in transcatheter aortic valve replacement undergoing a paradigm shift. In: Circulation Journal. 2019 ; Vol. 83, No. 5. pp. 952-962.
@article{e42a2e9ecb224073a1f46de40625fd30,
title = "Current key issues in transcatheter aortic valve replacement undergoing a paradigm shift",
abstract = "As a new technology in the management of valvular heart disease, transcatheter aortic valve replacement (TAVR) has drawn much attention since its emergence. To date, numerous studies have investigated the safety and efficacy of TAVR in patients of various risk profiles with severe aortic stenosis (AS) and demonstrated comparable or superior outcomes of TAVR when compared with surgical aortic valve replacement (SAVR). The favorable outcomes of TAVR in inoperable patients, as well as in high- and intermediaterisk patients, are endorsed in current guidelines, and trials of low-risk patients have shown non-inferior or even superior results of TAVR than for SAVR, suggesting that the clinical indications of TAVR can be expanded to low-risk patients. Moreover, a therapeutic role of TAVR has been suggested in various aortic valve (AV) diseases, such as bicuspid AV, moderate AS with heart failure, aortic regurgitation, and bioprosthetic valve failure. In this review, we summarize the current issues of TAVR in various patient populations and discuss the expanding clinical indications of TAVR, which are driving a major paradigm shift in the management of AV disease.",
keywords = "Aortic stenosis, Surgical aortic valve replacement, Transcatheter aortic valve implantation, Transcatheter aortic valve replacement, Valve-in-valve",
author = "Hwang, {In Chang} and Kentaro Hayashida and Kim, {Hyo Soo}",
year = "2019",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-19-0096",
language = "English",
volume = "83",
pages = "952--962",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "5",

}

TY - JOUR

T1 - Current key issues in transcatheter aortic valve replacement undergoing a paradigm shift

AU - Hwang, In Chang

AU - Hayashida, Kentaro

AU - Kim, Hyo Soo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - As a new technology in the management of valvular heart disease, transcatheter aortic valve replacement (TAVR) has drawn much attention since its emergence. To date, numerous studies have investigated the safety and efficacy of TAVR in patients of various risk profiles with severe aortic stenosis (AS) and demonstrated comparable or superior outcomes of TAVR when compared with surgical aortic valve replacement (SAVR). The favorable outcomes of TAVR in inoperable patients, as well as in high- and intermediaterisk patients, are endorsed in current guidelines, and trials of low-risk patients have shown non-inferior or even superior results of TAVR than for SAVR, suggesting that the clinical indications of TAVR can be expanded to low-risk patients. Moreover, a therapeutic role of TAVR has been suggested in various aortic valve (AV) diseases, such as bicuspid AV, moderate AS with heart failure, aortic regurgitation, and bioprosthetic valve failure. In this review, we summarize the current issues of TAVR in various patient populations and discuss the expanding clinical indications of TAVR, which are driving a major paradigm shift in the management of AV disease.

AB - As a new technology in the management of valvular heart disease, transcatheter aortic valve replacement (TAVR) has drawn much attention since its emergence. To date, numerous studies have investigated the safety and efficacy of TAVR in patients of various risk profiles with severe aortic stenosis (AS) and demonstrated comparable or superior outcomes of TAVR when compared with surgical aortic valve replacement (SAVR). The favorable outcomes of TAVR in inoperable patients, as well as in high- and intermediaterisk patients, are endorsed in current guidelines, and trials of low-risk patients have shown non-inferior or even superior results of TAVR than for SAVR, suggesting that the clinical indications of TAVR can be expanded to low-risk patients. Moreover, a therapeutic role of TAVR has been suggested in various aortic valve (AV) diseases, such as bicuspid AV, moderate AS with heart failure, aortic regurgitation, and bioprosthetic valve failure. In this review, we summarize the current issues of TAVR in various patient populations and discuss the expanding clinical indications of TAVR, which are driving a major paradigm shift in the management of AV disease.

KW - Aortic stenosis

KW - Surgical aortic valve replacement

KW - Transcatheter aortic valve implantation

KW - Transcatheter aortic valve replacement

KW - Valve-in-valve

UR - http://www.scopus.com/inward/record.url?scp=85065219426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065219426&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-19-0096

DO - 10.1253/circj.CJ-19-0096

M3 - Article

C2 - 30956265

AN - SCOPUS:85065219426

VL - 83

SP - 952

EP - 962

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 5

ER -